Until recently, little attention was paid to various aspects of the problem of additional vaccines, but they are all very important. This is where creativity and new strategies are particularly needed. New vaccines will not only save many lives - their presence will support the enthusiasm of political leaders in developing countries for the creation of national infrastructures needed to meet the goals of the FIR, namely, to fully vaccinate every child and maintain a high level of immunization coverage.
The UN does not ignore the problem of new vaccines. WHO is doing its utmost to promote research into the development and testing of new vaccines against infectious diseases for developing countries; this is served by five WHO programs covering vaccine research worldwide. However, in 1987, WHO’s cumulative budget for research and development of vaccines was only $ 10 million per year, which is very small, considering that $ 30–50 million is required for the development of only one vaccine. .
There are many obstacles to the creation and distribution of the necessary vaccines, and one of the most important is that the decision to develop new vaccines remains almost entirely in the hands of several institutions and commercial producers in developed countries. Technical knowledge and professional experience are concentrated in these numerous scientific institutes and firms, and some of them chose not to participate in the FIR. Commercial producers, in particular, tend to work for the needs of prosperous industrialized countries and are eager to fill their development costs, and then consider selling their products at a price close to the cost price.
For example, vaccine manufacturers in the United States, Canada, Western Europe, and Japan have focused largely on improving the pertussis component of the combined pertussis-diphtheria-tetanus vaccine (DPT), which in rare cases causes seizures and brain damage. The new vaccine will certainly be expensive - its cost will be 10-100 times the current price for the FIR. Additional costs, even if EPI could afford them, would not lead to an increase in the effectiveness of vaccination, coverage of new population groups or protection from new diseases.
Despite this uninspiring picture, the old expectation strategy to cover the costs of research and development and the subsequent acquisition of large quantities of products at a sharply reduced price, is still effective in the case of vaccines that have an extensive market in developed countries or some market for travelers. However, it will be a long wait. When new vaccines enter the market, they are usually expensive, not only because you need to recoup the usual costs of creating them, but also because new (and therefore expensive) technology is often used to make them. New technology is not always a necessity. It has repeatedly happened that it was preferred by the old technology, since the new method of production influenced the quality of the vaccine, for example, its side effect was weakened to some extent or its efficiency was somewhat increased. But it is often done at the expense of health care, creating products that are unacceptable in value for the third world countries.
One such drug that is already on the market is the hepatitis B vaccine. Kazançlar ve hediyeler için bu linke gir 1xbet mobil .
